New Lab Features Installation of Stereotaxis Magnetic Navigation System at
Prestigious Research Center
ST. LOUIS, Dec. 4 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today the official opening of the Stereotaxis Magnetic Navigation System at the new electrophysiology (EP) lab at the University Hospital of Bordeaux, France. The lab is headed by Professors Michel Haissaguerre and Pierre Jais, whose discovery of the ectopic foci that trigger atrial fibrillation (AF) in 1998 paved the way for new ablation techniques for more effectively treating this disease which affects millions of people worldwide.
The new EP lab was unveiled today in a ceremony at which Alain Heriaud, General Director of CHU of Bordeaux, Bevil Hogg, CEO of Stereotaxis and Alain Juppe, Mayor of Bordeaux and president of the board of directors of CHU of Bordeaux, presided.
"We are very enthusiastic about the present and future applications for the Stereotaxis system, which represents an engineering tour de force," said Professor Haissaguerre. "Today the Stereotaxis system allows stable and precise catheter positioning potentially better than manual manipulation. Our initial experience on atrial fibrillation using the magnetic irrigated catheter is very promising, suggesting notably the potential for a higher safety margin in comparison with conventional manipulation while maintaining at least equivalent efficacy."
"Our next goal is to achieve complete automation of the many different techniques necessary for catheter ablation of cardiac arrhythmias and particularly atrial fibrillation. We hope our partnership with Stereotaxis will be mutually beneficial in achieving our goals of further understanding and treating the most complex rhythm disturbances leading to better patient care," Professor Haissaguerre concluded.
"The installation of the Stereotaxis Niobe(R) system in Bordeaux represents a significant milestone for us, and we are particularly honored that the system has been installed at the University Hospital of Bordeaux, one of the leading research institutions in the world for electrophysiology," said Bevil Hogg, CEO of Stereotaxis. "We are also proud to note that Bordeaux has installed the Stereotaxis system with an Odyssey(TM) Network Solution. Odyssey is a powerful fully-networked user interface that consolidates the multiple information sources and systems of a traditional electrophysiology lab into one large screen with single mouse control, and has the potential to contribute significantly to procedure room simplification and work-flow productivity, and through its private network, to promote the dissemination of best practices worldwide."
"The recent launch of our partnered irrigated catheter has now expanded to multiple sites in Europe, and we are very pleased with the initial results," continued Mr. Hogg. "A significant number of cases using the irrigated catheter have now been performed, and we are gratified to note the high success rate in terms of outcomes and patient safety."
"Professor Haissaguerre and his team are pioneers in the discovery of new approaches to the treatment of AF and we look forward to using our collaboration with the Bordeaux team to advance scientific understanding and treatment of cardiac arrhythmias. We are honored to pay tribute to this esteemed team by participating in the opening of their new EP lab," concluded Mr. Hogg.
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. Stereotaxis has research agreements with certain leading institutions worldwide, including Bordeaux, France. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada. Note that use of cardiac ablation catheters for treatment of atrial fibrillation is considered investigational in the United States.
About Forward Looking Statements
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
|SOURCE Stereotaxis, Inc.|
Copyright©2007 PR Newswire.
All rights reserved